Regeneron Pharmaceuticals | Community Health

Regeneron Pharmaceuticals, Inc. is a leading American biotechnology company founded in 1988 by Leonard Schleifer, George Yancopoulos, and Eric M. Shooter. Headquartered in Westchester County, New York, Regeneron has evolved from its initial focus on neurotrophic factors to become a major player in the development of therapies targeting cytokine and tyrosine kinase receptors. With a strong pipeline of products, including the VEGF-trap, Regeneron has made significant contributions to the treatment of various diseases, including eye diseases, cancer, and inflammatory conditions. As of 2022, Regeneron's market capitalization exceeds $60 billion, solidifying its position as a key player in the biotech industry. Regeneron's commitment to innovation and its collaborative approach with research institutions, such as the [[national-institutes-of-health|National Institutes of Health]], have led to numerous breakthroughs, including the development of [[dupixent|Dupixent]] for atopic dermatitis and [[eylea|Eylea]] for age-related macular degeneration. With over 8,000 employees and a global presence, Regeneron continues to push the boundaries of medical science, exploring new frontiers in gene therapy, immunology, and beyond, as seen in its partnership with [[sanofi|Sanofi]] to develop innovative treatments.